IMGN / ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The compan more_horizontal

ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European more_horizontal

Subscribers to  Chart of the Week  received this commentary on Sunday, August 27. more_horizontal

Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuxi more_horizontal

Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with more_horizontal

Subscribers to Schaeffer's Event Trader  service scored a 272% profit with our  ImmunoGen, Inc. (NASDAQ:IMGN) August 17 put recommendation. more_horizontal

ImmunoGen (IMGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0 more_horizontal

ImmunoGen (IMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IMGN broke throug more_horizontal